AI assistant
Axogen, Inc. — Director's Dealing 2012
Mar 22, 2012
32414_dirs_2012-03-22_a15be807-2a5f-4862-9ee0-bbcd833a9300.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3/A — Form 3/A
Issuer: AxoGen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2011-09-30
Reporting Person: Zaderej Karen L. (Director, Chief Executive Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $0.2683 | 2016-06-07 | Common Stock (3348) | Direct | |
| Employee Stock Option (right to buy) | $0.2683 | 2017-04-27 | Common Stock (1398) | Direct | |
| Employee Stock Option (right to buy) | $0.2683 | 2017-12-06 | Common Stock (16773) | Direct | |
| Employee Stock Option (right to buy) | $0.2683 | 2017-12-06 | Common Stock (674) | Direct | |
| Employee Stock Option (right to buy) | $0.2683 | 2018-11-18 | Common Stock (507) | Direct | |
| Employee Stock Option (right to buy) | $0.2683 | 2020-06-09 | Common Stock (144445) | Direct |
Footnotes
F1: All of these options have vested.
F2: These options vest semi-annually over four years from the date of grant.
F3: Amended to correct mistake in option exercise price after appropriate application of conversion ratio as explained in footnotes.
F4: Pursuant to an Agreement and Plan of Merger, dated as of May 31, 2011, by and among LecTec Corporation ("LecTec"), Nerve Merger Sub Corp., a subsidiary of LecTec ("Merger Sub"), and AxoGen Corporation ("AC"), which the parties amended on June 30, 2011 and August 9, 2011 (as amended, the "Merger Agreement"), Merger Sub merged with and into AC, with AC continuing after the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the "Merger"). The Merger was completed on September 30, 2011, and LecTec was renamed AxoGen, Inc. ("AxoGen"). In connection with the Merger, each share of AC common stock converted into 0.03727336 share of LecTec common stock at the effective time of the Merger. In connection with the Merger, each option to purchase shares of AC common stock was converted tor an option to purchase 0.03727336 of a share of AxoGen common stock.
F5: 13,978 options have vested, and 2,795 options are unvested.
F6: 562 options have vested, and 112 options are unvested
F7: 317 options have vested, and 190 options are unvested.
F8: 36,111 options have vested, and 108,334 options are unvested.